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The nucleotide-binding oligomerization domain (NOD) proteins NOD1 and NOD2, the founding members of
the intracellular NOD-like receptor family, sense conserved motifs in bacterial peptidoglycan and induce
proinflammatory and antimicrobial responses. Here, we discuss recent developments about themechanisms
by which NOD1 and NOD2 are activated by bacterial ligands, the regulation of their signaling pathways, and
their role in host defense and inflammatory disease. Several routes for the entry of peptidoglycan ligands
to the host cytosol to trigger activation of NOD1 and NOD2 have been elucidated. Furthermore, genetic
screens and biochemical analyses have revealed mechanisms that regulate NOD1 and NOD2 signaling.
Finally, recent studies have suggested several mechanisms to account for the link between NOD2 variants
and susceptibility to Crohn’s disease. Further understanding of NOD1 and NOD2 should provide new insight
into the pathogenesis of disease and the development of new strategies to treat inflammatory and infectious
disorders.Introduction
The innate immune system carries out important functions,
including the recognition and clearance of infectious organisms
through the detection of microorganisms by germline-encoded
pathogen recognition receptors (PRRs). The nucleotide-binding
oligomerization domain (NOD) proteins NOD1 and NOD2 repre-
sent two well-characterized PRRs of the NOD-like receptor
(NLR) family; they sense conserved fragments found in the cell
wall of many types of bacteria and activate intracellular signaling
pathways that drive proinflammatory and antimicrobial re-
sponses. In contrast to PRRs such as Toll-like receptors
(TLRs), which recognize microbial ligands at the cell surface or
within endosomes, NOD1 and NOD2 sense bacterial products
in the host cytosol to provide another level of microbial surveil-
lance that is often associated with pathogen invasion. Here, we
focus on recent discoveries of the molecular mechanisms that
regulate NOD1 and NOD2 activation and signaling, the disrup-
tion of these pathways in inflammatory diseases, and efforts to
develop small molecules capable of modulating these pathways
for therapeutic applications. Specifically, we highlight recent
knowledge about the mechanism of recognition and activation
of NOD receptors, regulation of NOD1 and NOD2 signaling path-
ways, and new evidence linking NOD2 to the development of
Crohn’s disease (CD).
NOD1 and NOD2: Ligand Recognition and Activation
Sequence-homology searches identified NOD1 as the first NLR
member (Bertin et al., 1999; Inohara et al., 1999).NOD1 encodes
an intracellular multidomain scaffolding protein consisting of a
caspase activation and recruitment domain (CARD), a NOD,
and multiple leucine-rich repeats (LRRs). This led to the discov-
ery of NOD2, a closely related protein with an additional CARD
(Ogura et al., 2001b). Early work showed that NOD1 and NOD2
mediate activation of the nuclear factor kappa B (NF-kB) family
of transcriptional regulators in response to distinct peptido-898 Immunity 41, December 18, 2014 ª2014 Elsevier Inc.glycan (PGN) fragments (Inohara et al., 2001). Subsequent
studies demonstrated that NOD1 can be activated by g-D-glu-
tamyl-meso-diaminopimelic acid (iE-DAP), a motif present in
many Gram bacteria and certain Gram+ bacteria (Chamaillard
et al., 2003a; Girardin et al., 2003a; Hasegawa et al., 2006). Addi-
tional work revealed that muramyl dipeptide (MDP), a PGN motif
widely distributed among both Gram+ and Gram bacteria, is
sufficient to trigger NOD2 activity (Girardin et al., 2003b; Inohara
et al., 2003). Ultimately, NOD1 and NOD2 signaling contributes
to host defense via the production of proinflammatory cytokines
and antimicrobial molecules (Kobayashi et al., 2005; Masumoto
et al., 2006).
The mechanisms by which bacterial PGN enters cells and ac-
tivates NOD1 and NOD2 receptors remain poorly understood,
but multiple routes of entry have been reported (Figure 1). Two
recent studies have revealed a role for endosomes in the activa-
tion of NOD1 and NOD2 signaling (Irving et al., 2014; Nakamura
et al., 2014). In one study, two peptide transporters, SLC15A3
and SLC15A4, were shown to transport MDP across endosome
membranes of phagosomes that had internalized bacteria via
phagocytosis, and NOD1 and NOD2 localized to these mem-
branes (Nakamura et al., 2014). This study is consistent with
previous reports showing decreased NOD1-mediated cytokine
production in Slc15A4/ mice (Sasawatari et al., 2011) and
reduced NF-kB activation after NOD1 stimulation upon
SLC15A4 downregulation (Lee et al., 2009). Notably, SLC15A3
is present near a susceptibility locus associated with CD by a
genome-wide association study (Jostins et al., 2012). Although
the subcellular localization and expression of NOD1 and NOD2
vary depending on the cell type, the source and route of entry
of the ligand also influence NOD1 and NOD2 complex formation.
Indeed, outer membrane vesicles (OMVs) from a variety of bac-
teria (Irving et al., 2014; Thay et al., 2014) activate NOD1 and
NOD2 signaling, revealing an important role for vesicle internali-
zation in the delivery of ligands to cytosolic NOD1 and NOD2
Figure 1. Potential Mechanisms for Bacterial Recognition by NOD1 and NOD2
NOD1 and NOD2 sense intracellular PGN fragments from bacteria. Host cells can internalize PGNs by multiple routes, such as (1) phagocytosis of bacteria and
subsequent bacterial degradation, (2) uptake of PGN fragments from bacteria-derived extracellular OMVs, (3) transport across host membranes via channels,
pore-forming molecules, or bacterial secretion systems, (4) endocytosis, or (5) from neighboring cells. Once inside the cell, NOD1 and NOD2 activation typically
involves their relocalization to various intracellular locations, such as the plasma and endosomalmembranes, via different adaptormolecules that are differentially
expressed in host cells. For example, the activation of NOD2 by intracellular pathogens induces the formation of an autophagosome, which is mediated by
ATG16L1.
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cient to stimulate host cells, there are clearly multiple routes for
these molecules to enter the cell.
Although the role of NOD1 and NOD2 in sensing bacterial PGN
fragments has been reported for over a decade, it remains un-
clear whether these receptors respond directly to bacterially
derivedmolecules or indirectly through some other intermediate.
Recent experimental evidence supports a direct interaction be-
tween bacterial L-Ala-g-D-Glu-mesoDAP (Tri-DAP) and NOD1
by surface plasmon resonance (SPR) and atomic force micro-
scopy (Laroui et al., 2011) and between MDP and NOD2 by
SPR (Grimes et al., 2012) and biotin-labeled MDP pull-downs
(Mo et al., 2012). Although these studies agree on a direct inter-
action between receptor and ligand, the SPR data suggest a role
for the LRRs of both NOD1 and NOD2 in mediating the interac-
tion, whereas the pull-down experiments implicate the NOD re-
gion. Notably, SPR analysis between NOD2 and MDP revealed
a relatively high-affinity interaction (Kd  50 nM), whereas the
NOD1-Tri-DAP interaction was significantly weaker (Kd 
30 mM), which might reflect differences in the ligand used or in
assay conditions. A direct interaction between labeled PGN frag-
ments and NOD1 is also supported by fluorescence energy
transfer (Irving et al., 2014). Together, these studies support a
direct interaction between NOD1 and NOD2 and their bacterial
ligands, but they do not rule out a role for accessory molecules
that might facilitate ligand recognition, similar to the function ofMD-2 as a TLR4 coreceptor for bacterial lipopolysaccharide
(LPS) (Park et al., 2009). Further studies to define the molecular
details of these interactions will require structural data.
Existing structural analyses of the NLR family member NLRC4
and Apaf-1, an NLR-related protein that regulates apoptosis,
have provided insight into potential mechanisms of NOD1 and
NOD2 activation (Hu et al., 2013; Park et al., 2009). NOD1 and
NOD2 share a NOD module composed of a nucleotide-binding
domain (NBD), a winged helix (WH), and helix domains (HD1
and HD2). The ADP-mediated interaction between the NBD
and the WH is important for stabilizing the closed conformation,
whereas the LRRs occlude these domains to render NLR pro-
teins in a monomeric state (Hu et al., 2013). Upon ligand binding
to the LRRs, HD2 mediates conformational changes of the NBD,
WH, and HD1 to allow ADP-ATP exchange, self-oligomerization,
and downstream signaling (Lechtenberg et al., 2014; Riedl et al.,
2005). Consistently, HD2 variants in NOD2 result in either gain or
loss of function (Hu et al., 2013; Tanabe et al., 2004). Further-
more, similar gain- and loss-of-function NOD2 variants are asso-
ciated with early-onset sarcoidosis (EOS) or Blau syndrome and
CD, respectively (Caso et al., 2014; Franchi et al., 2009).
Complementation between NOD2 variants in HD2 and LRRs
further supports this mechanism of NOD2 activation (Tanabe
et al., 2004). Collectively, available evidence suggests that
NOD1 and NOD2 reside in an autoinhibited monomeric state
in the cytosol, and upon ligand recognition, they undergoImmunity 41, December 18, 2014 ª2014 Elsevier Inc. 899
Figure 2. NOD2 Signaling Pathways for Gene Activation
NOD2 interacts directly with intracellular bacterial PGN fragments containing the MDP motif. Ligand recognition relieves intramolecular autoinhibitory in-
teractions, leading toNODoligomerization. Recruitment of the downstream serine/threonine kinase (S/T kinase) RIPK2 occurs throughCARD-CARD interactions.
Subsequent activation of the NF-kB andMAPK pathways results in the transcriptional upregulation of proinflammatory and host-defense genes. Multiple steps in
the pathway are regulated either positively or negatively by posttranslational modifications, such as phosphorylation and pUb events. Multiple regulatory genes
act to influence various steps in the pathway, often in a cell-type-dependent manner. LUBAC stands for linear pUb chain assembly complex.
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further studies, including structural data to elucidate the regula-
tion of NOD1 and NOD2 activation, are needed.
NOD1 and NOD2 Signaling and Regulation
Once the conformation of NOD1 and NOD2 is open, the proteins
self-oligomerize and recruit receptor-interacting serine/threo-
nine-protein kinase 2 (RIPK2) through homotypic CARD-CARD
interactions, resulting in close proximity of RIPK2-IkB kinase
(IKK) complexes (Inohara et al., 1999). RIPK2 then mediates900 Immunity 41, December 18, 2014 ª2014 Elsevier Inc.the recruitment and activation of the serine/threonine kinase
TAK1, which is a prerequisite for activation of the IKK complex
and MAPK pathway (Figure 2). IKK-mediated phosphorylation
of the NF-kB inhibitor IkBa leads to its polyubiquitination (pUb)
and subsequent degradation through the proteasome, allowing
NF-kB to translocate to the nucleus and influence the expression
of downstream target genes. The posttranslation modification of
proteins with ubiquitin (Ub) affects many steps in the NF-kB
pathway. For example, NOD1 and NOD2 signaling is regulated
via Lys63-linked pUb of RIPK2 on Lys209, which is necessary
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Ogura et al., 2001b). Multiple groups have identified several
different E3 ligases capable of binding and catalyzing Lys48-
linked RIPK2 pUb, including cellular inhibitor of apoptosis 1
(cIAP1) and cIAP2 (Bertrand et al., 2009), ITCH (Tao et al.,
2009), and Pellino3 (Yang et al., 2013), suggesting a role for these
proteins in regulating NOD1 and NOD2 signaling. Notably, like
variants in NOD2, variants in X-linked inhibitor of apoptosis pro-
tein (XIAP), an E3 ligase that binds and polyubiquitinates RIPK2,
are associated with CD (Zeissig et al., 2014) and impaired NOD1
and NOD2 signaling (Damgaard et al., 2013). Additional E3
ligases that influence NOD1 and NOD2 signaling, including
TNF-receptor-associated factor 2 (TRAF2) and TRAF5 (Hase-
gawa et al., 2008), TRAF4 (Marinis et al., 2011), and RNF34
(Zhang et al., 2014), have been identified. The linear Ub chain
assembly complex, which consists of the E3 ligase RNF31
(also known as HOIP) and directs the linear pUb of NF-kB essen-
tial modulator (NEMO), also plays a positive role in NOD2-
induced NF-kB signaling (Damgaard et al., 2012).
The removal of Ub by proteases can further fine tune NOD1
and NOD2 signaling. For instance, A20 was the first Ub protease
identified to negatively regulate NOD2 signaling (Hitotsumatsu
et al., 2008). More recently, the deubiquitinase OTULIN was
shown to dampen NOD2 signaling (Fiil et al., 2013), and inhibition
of the Ub-specific protease USP8 and several of its interacting
partners also negatively regulates NOD2-induced interleukin-8
(CXCL8) production (Warner et al., 2014). Other roles for Ub in
the regulation of NOD1 and NOD2 signaling have been revealed.
For example, NOD2 is destabilized by Lys48-linked pUb and
subsequent degradation via the E3 ligase TRIM27 (Lee et al.,
2012; Zurek et al., 2012). This might partially account for the
phenomenon ofMDP tolerance, whereMDP pretreatment signif-
icantly decreases subsequent NOD2 activation upon restimula-
tion with MDP in both human cells (Hedl et al., 2007) and mouse
cells (Kim et al., 2008a). Similarly, direct pUb of NOD1 has been
reported (Zhang et al., 2014). Structural details of the interaction
between the CARD of NOD1 and Ub have also been resolved by
nuclear magnetic resonance (Ver Heul et al., 2013) and X-ray
crystallography (Ver Heul et al., 2014). Interestingly, analogous
to variants in the Ub-interacting interface of NOD1, variants in
the CARD of NOD2 result in loss of Ub binding and increased
NOD2-induced CXCL8 secretion.
NOD1 and NOD2 Function in Pathogen Recognition and
Immunity
Consistent with a role for NOD1 and NOD2 in host responses
against bacterial infection, Nod1/ and Nod2/ mice show
enhanced susceptibility to several pathogens (Franchi et al.,
2009; Philpott et al., 2014). Because bacteria can be sensed
by multiple PRRs, it is not surprising that in most cases, defi-
ciency of NOD1 and/or NOD2 has only modest effects on path-
ogen clearance in vivo (Philpott et al., 2014). Consistently, NOD1
and NOD2 play redundant roles with TLRs in the detection of
bacteria and the production of proinflammatorymolecules, given
that both signaling pathways lead to NF-kB andMAPK activation
(Park et al., 2007; Tada et al., 2005). A cooperative role for TLR4
and NOD1 was also revealed in the mobilization of mature he-
matopoietic stem cells to the spleen upon Escherichia coli infec-
tion (Burberry et al., 2014). Furthermore, the activity of NOD1 andNOD2 becomes important when TLR signaling is absent or
reduced in vivo (Kim et al., 2008b). In line with these observa-
tions, TLR-ligand-insensitive epithelial cells still respond to
NOD1 ligands and NOD1-stimulatory bacteria (Kim et al.,
2004). Additionally, NOD1 and NOD2 signaling is enhanced by
pretreatment with TLR ligands, such as LPS or viral infection
through a type-I-interferon (IFN)-dependent mechanism both
in vitro and in vivo (Kim et al., 2014).
NOD1 is widely expressed by a variety of cell types, such as
epithelial cells, stromal cells, and endothelial cells (Inohara
et al., 1999; Park et al., 2007). Stimulation of intestinal epithelial
cells with NOD1-activating molecules induces the production
of chemokines and the recruitment of acute inflammatory cells
in vivo (Masumoto et al., 2006). NOD1 contributes to the activa-
tion of immune responses in epithelial cells infected with several
Gram bacteria, including Shigella flexneri (Girardin et al., 2003a;
Kim et al., 2010) and Helicobacter pylori (Allison et al., 2009). In
both infection models, either intracellular delivery of S. flexneri
LPS-containing NOD1 ligand or injection of H. pylori PGN frag-
ments via a type IV secretion system promotes NOD1-depen-
dent activation of NF-kB in epithelial cells (Allison et al., 2009;
Girardin et al., 2001). H. pylori can also induce the synthesis of
type I IFN via NOD1 (Watanabe et al., 2010), and consequently,
Nod1/ mice are more susceptible to H. pylori infection,
demonstrating the importance of NOD1 in pathogen recognition
in vivo (Viala et al., 2004).
NOD1 is also involved in the sensing of enteroinvasive E. coli
(Kim et al., 2004), Pseudomonas aeruginosa (Travassos et al.,
2005), Campylobacter jejuni (Zilbauer et al., 2007), Pasteurella-
ceae NI1060 (Jiao et al., 2013), and Gram+ Clostridium difficile
(Hasegawa et al., 2011). Consistently, Nod1/ mice are more
susceptible to C. difficile infection, which is associated with
impaired C. difficile clearance, increased commensal transloca-
tion, and defective recruitment of neutrophils to the infected site
(Hasegawa et al., 2011). Similarly, NOD1 is important for neutro-
phil recruitment in response to accumulation of the pathobiont
NI1060 at damaged gingival sites, which results in mouse
periodontitis (Jiao et al., 2013). Furthermore, Nod1/ mice
show increased susceptibility to lung infection with Legionella
pneumophila, which is associated with reduced neutrophil
recruitment to the lungs (Frutuoso et al., 2010).
In contrast to NOD1 expression, NOD2 expression is limited to
certain cell types, such as hematopoietic cells (Ogura et al.,
2003). In the intestine, NOD2 is expressed in Paneth cells and
stem cells (Barnich et al., 2005; Nigro et al., 2014), where it
senses many types of PGNs, which vary in their level of NOD2-
stimulatory activity across bacterial species (Hasegawa et al.,
2006), and activates NF-kB and MAPK signaling in the context
of Streptococcus pneumoniae (Opitz et al., 2004) and E. coli
(Theivanthiran et al., 2012) infections. NOD2 is also involved in
sensing intracellular Listeria monocytogenes (Kobayashi et al.,
2005), Salmonella typhimurium (Hisamatsu et al., 2003),
S. flexneri (Kufer et al., 2006), and Mycobacterium tuberculosis
(Ferwerda et al., 2005). Several studies have reported a role for
NOD2 in host defense in vivo. For instance, S. pneumoniae
recognition by NOD2 induces the production of CC-chemokine
ligand 2 (CCL2), leading to the recruitment of inflammatory mac-
rophages that are necessary for bacteria clearance in the lung
(Davis et al., 2011). Similarly, NOD2 promotes the clearance ofImmunity 41, December 18, 2014 ª2014 Elsevier Inc. 901
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(Th1) cell immune responses in the intestine (Kim et al., 2011a)
and of Staphylococcus aureus in the skin (Hruz et al., 2009).
Given the role of both NOD1 and NOD2 in the innate immune
response against bacterial pathogens, it is not surprising that
pathogens have evolved mechanisms to evade detection and
clearance by the host. Indeed, L. monocytogenes can escape
NOD1-mediated detection by modifying its PGN via N-deacety-
lation (Boneca et al., 2007). A similar evasion mechanism,
through the modification of cell-wall PGNs, has also been
described for H. pylori to avoid NOD1-mediated detection (Cha-
put et al., 2006).
In addition to evidence of the role of NOD proteins in innate
immune responses to bacterial infections, there is mounting
evidence that NOD1 and NOD2 signaling influences adaptive
immune responses. PGN derivatives have been identified as
adjuvants of antigen-specific immunoglobulin G (IgG) production
(Ellouz et al., 1974). As expected, the adjuvant activity of MDP,
including antigen-specific IgG responses, was mediated by
NOD2 in vivo (Girardin et al., 2003b; Inohara et al., 2003; Kobaya-
shi et al., 2005). NOD2 also regulates Th17 cell responses (Brain
et al., 2013; van Beelen et al., 2007). In mice, stimulation with
either NOD1 or NOD2 alone leads to predominantly Th2-cell-
dependent adaptive immune responses, whereas costimulation
with TLR agonists promotes the priming of Th1, Th2, and Th17
cell immune responses (Fritz et al., 2007; Magalhaes et al.,
2008). Furthermore, NOD1 and NOD2 stimulation induces
OX40 ligand, which is important for Th2-cell-oriented acquired
immunity (Duan et al., 2010; Magalhaes et al., 2011). Both
NOD1 and NOD2 contribute to IL-6-dependent induction of
mucosal Th17 cell responses during early stages of intestinal
infection with C. rodentium and S. typhimurium (Geddes et al.,
2011). Notably, radiation-resistant nonhematopoietic cells play
a role in triggering NOD1-mediated Th2 cell immune responses
(Fritz et al., 2007), although the mechanisms involved remain un-
known. Together, these studies provide evidence of a role for
NOD1 and NOD2 signaling in regulating adaptive immune re-
sponses.
NOD2 is required for the ‘‘training’’ of monocytes induced by
tuberculosis vaccination. Indeed, monocytes can be functionally
reprogrammed to exhibit enhanced and lasting protective func-
tions not only against tuberculosis but also against secondary
nonmycobacterial challenges through a NOD2-dependent
mechanism (Kleinnijenhuis et al., 2012). Overall, this work sug-
gests a role for NOD2 in modulating the adaptive features of
innate immunity.
NOD2 Function and CD
Polymorphisms in NOD2 are the strongest known genetic risk
factors in the development of CD (Hugot et al., 2001; Ogura
et al., 2001a). Three common NOD2 variants (R702W, G908R,
and L1007insC) and multiple minor variants in the C-terminal
LRR region and HD2 are linked to the development of CD (Cha-
maillard et al., 2003b). Individuals with just one NOD2 variant
have an only mildly increased risk of developing CD, whereas
those homozygous or compound heterozygous for NOD2 vari-
ants exhibit a 20- to 40-fold increased risk (Hugot et al., 2007).
However, the majority of individuals homozygous for NOD2 var-
iants do not develop CD, indicating that environmental factors,902 Immunity 41, December 18, 2014 ª2014 Elsevier Inc.altered immune regulation, and/or the gut microbiota are critical
for disease development. Consistently, no spontaneous intesti-
nal inflammation occurs inNod2/mice or knockin mice homo-
zygous for the CD-associated L1007insC NOD2 variant and
housed under specific-pathogen-free facilities (Kim et al.,
2011b; Kobayashi et al., 2005; Pauleau and Murray, 2003).
The mechanisms by which NOD2 variants contribute to CD
pathogenesis remain unclear, but several hypotheses have
been proposed (Figure 3). The first suggests that NOD2 variants
lead to impairedNOD2 activation in response toMDP stimulation
and thus result in a loss-of-function phenotype (Inohara et al.,
2003). Consistently, induction of inflammatory cytokines after
MDP stimulation is impaired in monocytes homozygous for
CD-associated NOD2 variants (Inohara et al., 2003; van Heel
et al., 2005). Overall, this hypothesis suggests that NOD2 vari-
ants impair bacterial recognition and clearance and thus lead
to aberrant inflammation through NOD2-independent pathways.
Because monocytes and neutrophils express NOD2, defects in
bacterial recognition could involve phagocytic cells recruited to
intestinal sites (Ogura et al., 2001b). Furthermore, some intesti-
nal bacteria rely on NOD2 recognition for activation of innate
immune responses, but such recognition is impaired in macro-
phages harboring CD-associated NOD2 variants (Kim et al.,
2011b). Paneth cells that are located in the crypts of the small in-
testine and secrete antibacterial proteins and peptides such as
a-defensins express NOD2 (Lala et al., 2003; Ogura et al.,
2003). Notably, CD-associated NOD2 variants confer suscepti-
bility to the development of ileal, but not colonic, lesions, corre-
sponding to the location of Paneth cells (Gasche and Grundtner,
2005). Furthermore, altered expression of a-defensins was
observed in patients with ileal CD (Wehkamp et al., 2005). How-
ever, whether the reduced expression of a-defensins is a primary
pathogenic event or an epiphenomenon of inflammation reflect-
ing Paneth cell loss due to mucosal damage remains controver-
sial (Simms et al., 2008). In mice, NOD2 regulates the expression
of a subgroup of Paneth-cell-expressed a-defensins (Kobayashi
et al., 2005) and the accumulation of both commensal and path-
ogenic bacteria in the terminal ileum (Petnicki-Ocwieja et al.,
2009). However, other studies have shown no difference in the
expression of antimicrobial molecules between Nod2/ and
wild-type (WT) mice (Robertson et al., 2013; Shanahan et al.,
2014). So, it is still controversial whether CD-related inflamma-
tion is triggered by impaired antimicrobial activity within the
intestinal crypts and abnormal accumulation of pathogenic bac-
teria and/or pathobionts.
Initial work showed that compared to WT mice, Nod2/mice
have an altered composition of the gut microbiota with a net in-
crease in the abundance of Bacteroidetes and Firmicutes phyla
in the feces and terminal ileum (Petnicki-Ocwieja et al., 2009;
Rehman et al., 2011). However, other studies did not identify sig-
nificant differences in the composition of the gut microbial com-
munity in Nod2/mice (Robertson et al., 2013; Shanahan et al.,
2014), raising the possibility that the imbalance in bacterial com-
munities found in Nod2/mice might be due to maternal trans-
mission of the microbiota and/or other environmental factors
independent of genotype. However, the controversy of whether
NOD2 deficiency promotes dysbiosis requires further study
given that small intestinal abnormalities, including goblet cell
alterations (which are associated with an increased number of
Figure 3. NOD2 and CD
NOD2 plays a crucial role in regulating intestinal homeostasis. By sensing microbiota-derived PGN fragments, NOD2 activates NF-kB, which in turn leads to the
production of Paneth cell (PC) antimicrobial peptides (AMPs), which provide a barrier between the microorganisms and the epithelial layer. Activation of NOD2 in
dendritic cells (DCs) leads to the production of interleukin-23 (IL-23), thus promoting an early mucosal T helper 17 (Th17) cell response that enhances barrier
protection by inducing IL-22 and regenerating islet-derived protein IIIg (REGIIIg). NOD2 activation in stromal cells also promotes CCL2-mediated recruitment of
inflammatory monocytes (Mo) to the intestine. Interaction between NOD2 and ATG16L1 promotes autophagosome formation in intestinal epithelial cells (IECs)
and intraepithelial bacterial clearance. CD-associated NOD2 variants perturb many aspects of immune homeostasis, including reduced MDP sensing in both
macrophages (Mac) and DCs, impaired antimicrobial responses in PCs, and altered autophagy, leading to defective barrier function and/or bacterial clearance.
These alterations, along with the development of dysbiosis, could lead to enhancedmucosal adherence and translocation of bacteria. Other abbreviations are as
follows: GC, goblet cell; IEL, intraepithelial lymphocyte; and N, neutrophil.
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reported in Nod2/mice (Ramanan et al., 2014). Notably, these
abnormalities correlate with the selective expansion of the
commensal Bacteroides vulgatus, which can exacerbate
intestinal inflammation in Nod2/ mice treated with the NSAID
piroxicam. However, the biological relevance of these intestinal
alterations observed in Nod2/ mice and the relative abun-
dance of B. vulgatus in patients with CD need to be further
investigated.
Another hypothesis that links NOD2 variants to the develop-
ment of CD involves the recently recognized role of NOD2 in
the autophagy pathway. NOD2 interacts with and recruits the
CD-associated autophagy protein ATG16L1 to the plasmamem-
brane at bacterial entry sites (Travassos et al., 2010). Further-
more, NOD2 stimulation promotes host cell autophagosome
formation, which is associated with an increase in either killing
of S. typhimurium or antigen presentation (Cooney et al., 2010;
Homer et al., 2010). Notably, CD-associated NOD2 variantsare defective in ATG16L1 recruitment and exhibit impaired
bacteria-induced autophagy in a cell-type-specific manner
(Homer et al., 2010). Furthermore, patients with ileal CD have
impaired secretion of Paneth-cell-derived a-defensins, a defect
that can arise from mutations in NOD2 or autophagy genes
(Cadwell et al., 2008; Wehkamp et al., 2004; Wehkamp et al.,
2005). Loss of function of ATG16L1 has also been associated
with Paneth cell abnormalities in mice, although pathology asso-
ciated with Paneth cell function relies on prior exposure to
mouse norovirus (Cadwell et al., 2008; Cadwell et al., 2010).
However, no defects in autophagy have been reported in
Nod2/mice in vivo. Therefore, further work is needed to ascer-
tain the functional interplay between CD-associated NOD2 and
ATG16L1.
Finally, another hypothesis suggests that NOD2 negatively
regulates TLR signaling and that NOD2 variants result in deregu-
lated TLR signaling and enhanced inflammation. Consistently,
TLR-induced IL-12 production was increased in macrophagesImmunity 41, December 18, 2014 ª2014 Elsevier Inc. 903
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2006). This model proposes that NOD2 acts as a brake to
dampen immune responses and that NOD2 variants lead to a
deregulated TLR-mediated Th1 cell response in the intestine.
However, the bulk of studies have failed to reveal an increase
in the production of cytokines, such as IL-12, in macrophages
or human DCs deficient in NOD2 after TLR stimulation (Kim
et al., 2008b; Kramer et al., 2006; Park et al., 2007; Salucci
et al., 2008). Furthermore, NOD2 positively regulates the produc-
tion of IL-10 in response to microbial stimulation, and CD-asso-
ciated NOD2 variants inhibit MDP-induced IL10 transcription in
human monocytes (Noguchi et al., 2009; Wagener et al., 2014).
The latter most likely reflects, in part, the overall impairment of
immune responses to MDP in cells homozygous for CD-associ-
ated NOD2 mutations.
Early evidence showed that macrophages isolated from
knockin mice expressing the CD-associated L1007insC NOD2
variant exhibit increased NF-kB activation and IL-1b secretion
after MDP stimulation (Maeda et al., 2005). However, the inter-
pretation of the latter studies is difficult because subsequent
examination of this mouse model showed a duplication of the
30 end of theWTNod2 locus, which was targeted by themutation
(Maeda et al., 2005). Furthermore, an independently generated
knockin L1007insCNOD2mousemodel revealed that the variant
acts as a loss of function (Kim et al., 2011b), consistent with
human studies.
Potential for the Therapeutic Modulation of NOD1 and
NOD2 Signaling
Several groups are attempting to develop small molecules
capable of modulating NOD1 and NOD2 signaling in order to in-
fluence pathogen clearance and inflammation (Geddes et al.,
2009; Jakopin, 2014; Maisonneuve et al., 2014). For instance,
molecules capable of enhancing or blocking NOD2 signaling
would have application in diseases such as CD and EOS, which
have been associated with NOD2 loss- and gain-of-function var-
iants, respectively. The development of small molecules capable
of modulating NOD1 and NOD2 signaling might also have poten-
tial applications in other infectious and inflammatory diseases,
such asthma, arthritis, leprosy, graft versus host disease, and
periodontitis, which have each been associated with deregu-
lated NOD1 and/or NOD2 signaling (Correa et al., 2012; Jiao
et al., 2014; Philpott et al., 2014) but await further functional vali-
dation. One of the first successful approaches to modulating
NOD2 signaling with small molecules came from the develop-
ment of kinase inhibitors capable of blocking RIPK2 (Jun et al.,
2013; Tigno-Aranjuez et al., 2010; Tigno-Aranjuez et al., 2014),
and others have identified anti-inflammatory activities for diter-
pene-based molecules via their ability to specifically block
NOD2 signaling (Bielig et al., 2010). More recently, libraries of
small molecules were screened, identifying lead compounds
capable of influencing NOD1 (Khan et al., 2011; Rickard et al.,
2013) and NOD2 signaling (Correa et al., 2011; Rickard et al.,
2013). In most cases, the molecular mechanisms by which these
small molecules act to regulate NOD1 and NOD2 signaling
remain poorly understood. It is possible that these small mole-
cules act directly to affect NOD protein stability, ligand recogni-
tion, and/or ATP binding and hydrolysis activity. Alternatively,
theymight target any one of the numerous regulatory proteins re-904 Immunity 41, December 18, 2014 ª2014 Elsevier Inc.vealed by recent small interfering RNA screens to participate in
the NOD1 and NOD2 pathway (Lipinski et al., 2012; Warner
et al., 2014).
Although most of the small-molecule screens have identified
NOD1 and NOD2 inhibitors, some investigators have attempted
to identify NOD1 and NOD2 immunostimulatory molecules with
potential applications as vaccine adjuvants or antimicrobial
agents. Early efforts in this area involved the chemical modifica-
tion of core PGN ligands to enhance NOD1 and NOD2 activity.
Experiments on the relationship between structure and activity
revealed chemical modifications that either attenuate or
enhance the stimulatory activity of the NOD1 ligand iE-DAP
(Agnihotri et al., 2011; Jakopin et al., 2013) or MDP (Jakopin
et al., 2012; Rubino et al., 2013). These studies suggest that
new ligands can be developed to enhance NOD1 and NOD2
immunity.
In addition to evidence of the role of NOD1 and NOD2 in regu-
lating gut homeostasis and protection against colitis, there is
evidence that NOD1 and NOD2 regulate colitis-associated
cancer. For example, mice lacking NOD1 (Chen et al., 2008),
RIPK2, or NOD2 (Couturier-Maillard et al., 2013) develop more
tumors in colitis-associated colon cancer models. There is also
data suggesting a role for NOD1 and NOD2 in tumors outside
of the intestine (da Silva Correia et al., 2006). Together, these
studies support the modulation of NOD1 and NOD2 signaling
as a therapeutic strategy in the treatment of proinflammatory dis-
eases and cancers; however, additional studies will be required
for determining the negative and positive effects of targeting the
NOD1 and NOD2 pathway in order to balance the inhibition of
detrimental inflammation against immune suppression and sus-
ceptibility to infection.Concluding Remarks
Compelling evidence indicates that NOD1 and NOD2 are
involved in the recognition of highly conserved PGN molecules
that enter the host cytosol through phagocytosis, endocytosis,
endosomal membrane transporters, bacterial secretion sys-
tems, pore-forming toxins, or OMVs. NOD1 and NOD2 directly
recognize PGN molecules, leading to their activation and
induction of proinflammatory and antimicrobial molecules.
Biochemical analyses and genetic screens have revealed com-
plex mechanisms that regulate NOD1 and NOD2 signaling.
NOD1 and NOD2 play a role in the clearance of invading patho-
gens and act redundantly and cooperatively with TLRs in the
detection of bacteria and production of proinflammatory mole-
cules. Experimental evidence suggests several mechanisms by
which NOD2 variants regulate the susceptibility to CD. Although
our knowledge about NOD1 and NOD2 has increased, several
key questions—including the precise mechanism of NOD1 and
NOD2 activation by PGN molecules and how NOD2 acts in the
intestine to regulate susceptibility to CD—remain. Undoubtedly,
elucidating these questions will provide new insights into the
mechanisms of host defense and the pathogenesis of inflamma-
tory disease.ACKNOWLEDGMENTS
We thank Grace Chen for critically reviewing themanuscript. We acknowledge
funding from the NIH, the Crohn’s & Colitis Foundation of America, the Broad
Immunity
ReviewFoundation, the EMBO Fellowship Programme, and the Italian Group for In-
flammatory Bowel Diseases.REFERENCES
Agnihotri, G., Ukani, R., Malladi, S.S., Warshakoon, H.J., Balakrishna, R.,
Wang, X., and David, S.A. (2011). Structure-activity relationships in nucleotide
oligomerization domain 1 (Nod1) agonistic g-glutamyldiaminopimelic acid
derivatives. J. Med. Chem. 54, 1490–1510.
Allison, C.C., Kufer, T.A., Kremmer, E., Kaparakis, M., and Ferrero, R.L. (2009).
Helicobacter pylori induces MAPK phosphorylation and AP-1 activation via a
NOD1-dependent mechanism. J. Immunol. 183, 8099–8109.
Barnich, N., Hisamatsu, T., Aguirre, J.E., Xavier, R., Reinecker, H.C., and
Podolsky, D.K. (2005). GRIM-19 interacts with nucleotide oligomerization
domain 2 and serves as downstream effector of anti-bacterial function in intes-
tinal epithelial cells. J. Biol. Chem. 280, 19021–19026.
Bertin, J., Nir, W.J., Fischer, C.M., Tayber, O.V., Errada, P.R., Grant, J.R.,
Keilty, J.J., Gosselin, M.L., Robison, K.E., Wong, G.H., et al. (1999). Human
CARD4 protein is a novel CED-4/Apaf-1 cell death family member that acti-
vates NF-kappaB. J. Biol. Chem. 274, 12955–12958.
Bertrand, M.J., Doiron, K., Labbe´, K., Korneluk, R.G., Barker, P.A., and Saleh,
M. (2009). Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for
innate immunity signaling by the pattern recognition receptors NOD1 and
NOD2. Immunity 30, 789–801.
Bielig, H., Velder, J., Saiai, A., Menning, M., Meemboor, S., Kalka-Moll, W.,
Kro¨nke, M., Schmalz, H.G., and Kufer, T.A. (2010). Anti-inflammatory
arene—chromium complexes acting as specific inhibitors of NOD2 signalling.
ChemMedChem 5, 2065–2071.
Boneca, I.G., Dussurget, O., Cabanes, D., Nahori, M.A., Sousa, S., Lecuit, M.,
Psylinakis, E., Bouriotis, V., Hugot, J.P., Giovannini, M., et al. (2007). A critical
role for peptidoglycan N-deacetylation in Listeria evasion from the host innate
immune system. Proc. Natl. Acad. Sci. USA 104, 997–1002.
Brain, O., Owens, B.M., Pichulik, T., Allan, P., Khatamzas, E., Leslie, A., Stee-
vels, T., Sharma, S., Mayer, A., Catuneanu, A.M., et al. (2013). The intracellular
sensor NOD2 induces microRNA-29 expression in human dendritic cells to
limit IL-23 release. Immunity 39, 521–536.
Burberry, A., Zeng, M.Y., Ding, L., Wicks, I., Inohara, N., Morrison, S.J., and
Nu´n˜ez, G. (2014). Infection mobilizes hematopoietic stem cells through coop-
erative NOD-like receptor and Toll-like receptor signaling. Cell Host Microbe
15, 779–791.
Cadwell, K., Liu, J.Y., Brown, S.L., Miyoshi, H., Loh, J., Lennerz, J.K., Kishi, C.,
Kc, W., Carrero, J.A., Hunt, S., et al. (2008). A key role for autophagy and the
autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature
456, 259–263.
Cadwell, K., Patel, K.K., Maloney, N.S., Liu, T.C., Ng, A.C., Storer, C.E., Head,
R.D., Xavier, R., Stappenbeck, T.S., and Virgin, H.W. (2010). Virus-plus-sus-
ceptibility gene interaction determines Crohn’s disease gene Atg16L1 pheno-
types in intestine. Cell 141, 1135–1145.
Caso, F., Costa, L., Rigante, D., Vitale, A., Cimaz, R., Lucherini, O.M., Sfriso,
P., Verrecchia, E., Tognon, S., Bascherini, V., et al. (2014). Caveats and truths
in genetic, clinical, autoimmune and autoinflammatory issues in Blau syn-
drome and early onset sarcoidosis. Autoimmun. Rev. 13, 1220–1229, http://
dx.doi.org/10.1016/2014.08.10.
Chamaillard, M., Hashimoto, M., Horie, Y., Masumoto, J., Qiu, S., Saab, L.,
Ogura, Y., Kawasaki, A., Fukase, K., Kusumoto, S., et al. (2003a). An essential
role for NOD1 in host recognition of bacterial peptidoglycan containing diami-
nopimelic acid. Nat. Immunol. 4, 702–707.
Chamaillard, M., Philpott, D., Girardin, S.E., Zouali, H., Lesage, S., Chareyre,
F., Bui, T.H., Giovannini, M., Zaehringer, U., Penard-Lacronique, V., et al.
(2003b). Gene-environment interaction modulated by allelic heterogeneity in
inflammatory diseases. Proc. Natl. Acad. Sci. USA 100, 3455–3460.
Chaput, C., Ecobichon, C., Cayet, N., Girardin, S.E., Werts, C., Guadagnini, S.,
Pre´vost, M.C., Mengin-Lecreulx, D., Labigne, A., and Boneca, I.G. (2006). Role
of AmiA in the morphological transition of Helicobacter pylori and in immune
escape. PLoS Pathog. 2, e97.Chen, G.Y., Shaw, M.H., Redondo, G., and Nu´n˜ez, G. (2008). The innate im-
mune receptor Nod1 protects the intestine from inflammation-induced tumor-
igenesis. Cancer Res. 68, 10060–10067.
Cooney, R., Baker, J., Brain, O., Danis, B., Pichulik, T., Allan, P., Ferguson,
D.J., Campbell, B.J., Jewell, D., and Simmons, A. (2010). NOD2 stimulation in-
duces autophagy in dendritic cells influencing bacterial handling and antigen
presentation. Nat. Med. 16, 90–97.
Correa, R.G., Khan, P.M., Askari, N., Zhai, D., Gerlic, M., Brown, B., Magnu-
son, G., Spreafico, R., Albani, S., Sergienko, E., et al. (2011). Discovery and
characterization of 2-aminobenzimidazole derivatives as selective NOD1 in-
hibitors. Chem. Biol. 18, 825–832.
Correa, R.G., Milutinovic, S., and Reed, J.C. (2012). Roles of NOD1 (NLRC1)
and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci.
Rep. 32, 597–608.
Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A.,
Haesler, R., Huot, L., Grandjean, T., Bressenot, A., Delanoye-Crespin, A., et al.
(2013). NOD2-mediated dysbiosis predisposes mice to transmissible colitis
and colorectal cancer. J. Clin. Invest. 123, 700–711.
da Silva Correia, J.,Miranda, Y., Austin-Brown, N., Hsu, J.,Mathison, J., Xiang,
R., Zhou, H., Li, Q., Han, J., and Ulevitch, R.J. (2006). Nod1-dependent control
of tumor growth. Proc. Natl. Acad. Sci. USA 103, 1840–1845.
Damgaard, R.B., Nachbur, U., Yabal, M., Wong, W.W., Fiil, B.K., Kastirr, M.,
Rieser, E., Rickard, J.A., Bankovacki, A., Peschel, C., et al. (2012). The ubiqui-
tin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate
immunity. Mol. Cell 46, 746–758.
Damgaard, R.B., Fiil, B.K., Speckmann, C., Yabal, M., zur Stadt, U., Bekker-
Jensen, S., Jost, P.J., Ehl, S., Mailand, N., and Gyrd-Hansen, M. (2013).
Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent
immune signalling. EMBO Mol. Med. 5, 1278–1295.
Davis, K.M., Nakamura, S., and Weiser, J.N. (2011). Nod2 sensing of lyso-
zyme-digested peptidoglycan promotes macrophage recruitment and clear-
ance of S. pneumoniae colonization in mice. J. Clin. Invest. 121, 3666–3676.
Duan, W., Mehta, A.K., Magalhaes, J.G., Ziegler, S.F., Dong, C., Philpott, D.J.,
and Croft, M. (2010). Innate signals from Nod2 block respiratory tolerance and
program T(H)2-driven allergic inflammation. J. Allergy Clin. Immunol. 126,
1284–1293, e10.
Ellouz, F., Adam, A., Ciorbaru, R., and Lederer, E. (1974). Minimal structural
requirements for adjuvant activity of bacterial peptidoglycan derivatives.
Biochem. Biophys. Res. Commun. 59, 1317–1325.
Ferwerda, G., Girardin, S.E., Kullberg, B.J., Le Bourhis, L., de Jong, D.J., Lan-
genberg, D.M., van Crevel, R., Adema, G.J., Ottenhoff, T.H., Van der Meer,
J.W., and Netea, M.G. (2005). NOD2 and toll-like receptors are nonredundant
recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 1,
279–285.
Fiil, B.K., Damgaard, R.B., Wagner, S.A., Keusekotten, K., Fritsch, M., Bekker-
Jensen, S., Mailand, N., Choudhary, C., Komander, D., and Gyrd-Hansen, M.
(2013). OTULIN restricts Met1-linked ubiquitination to control innate immune
signaling. Mol. Cell 50, 818–830.
Franchi, L., Warner, N., Viani, K., and Nun˜ez, G. (2009). Function of Nod-like
receptors in microbial recognition and host defense. Immunol. Rev. 227,
106–128.
Fritz, J.H., Le Bourhis, L., Sellge, G., Magalhaes, J.G., Fsihi, H., Kufer, T.A.,
Collins, C., Viala, J., Ferrero, R.L., Girardin, S.E., and Philpott, D.J. (2007).
Nod1-mediated innate immune recognition of peptidoglycan contributes to
the onset of adaptive immunity. Immunity 26, 445–459.
Frutuoso, M.S., Hori, J.I., Pereira, M.S., Junior, D.S., Soˆnego, F., Kobayashi,
K.S., Flavell, R.A., Cunha, F.Q., and Zamboni, D.S. (2010). The pattern recog-
nition receptors Nod1 and Nod2 account for neutrophil recruitment to the
lungs of mice infected with Legionella pneumophila. Microbes Infect. 12,
819–827.
Gasche, C., and Grundtner, P. (2005). Genotypes and phenotypes in Crohn’s
disease: do they help in clinical management? Gut 54, 162–167.
Geddes, K., Magalha˜es, J.G., and Girardin, S.E. (2009). Unleashing the thera-
peutic potential of NOD-like receptors. Nat. Rev. Drug Discov. 8, 465–479.Immunity 41, December 18, 2014 ª2014 Elsevier Inc. 905
Immunity
ReviewGeddes, K., Rubino, S.J., Magalhaes, J.G., Streutker, C., Le Bourhis, L., Cho,
J.H., Robertson, S.J., Kim, C.J., Kaul, R., Philpott, D.J., and Girardin, S.E.
(2011). Identification of an innate T helper type 17 response to intestinal bac-
terial pathogens. Nat. Med. 17, 837–844.
Girardin, S.E., Tournebize, R., Mavris, M., Page, A.L., Li, X., Stark, G.R., Bertin,
J., DiStefano, P.S., Yaniv, M., Sansonetti, P.J., and Philpott, D.J. (2001).
CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella
flexneri. EMBO Rep. 2, 736–742.
Girardin, S.E., Boneca, I.G., Carneiro, L.A., Antignac, A., Je´hanno, M., Viala, J.,
Tedin, K., Taha, M.K., Labigne, A., Za¨hringer, U., et al. (2003a). Nod1 detects a
unique muropeptide from gram-negative bacterial peptidoglycan. Science
300, 1584–1587.
Girardin, S.E., Boneca, I.G., Viala, J., Chamaillard, M., Labigne, A., Thomas,
G., Philpott, D.J., and Sansonetti, P.J. (2003b). Nod2 is a general sensor of
peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem.
278, 8869–8872.
Grimes, C.L., Ariyananda, Lde.Z., Melnyk, J.E., and O’Shea, E.K. (2012). The
innate immune protein Nod2 binds directly to MDP, a bacterial cell wall frag-
ment. J. Am. Chem. Soc. 134, 13535–13537.
Hasegawa, M., Yang, K., Hashimoto, M., Park, J.H., Kim, Y.G., Fujimoto, Y.,
Nun˜ez, G., Fukase, K., and Inohara, N. (2006). Differential release and distribu-
tion of Nod1 andNod2 immunostimulatorymolecules among bacterial species
and environments. J. Biol. Chem. 281, 29054–29063.
Hasegawa, M., Fujimoto, Y., Lucas, P.C., Nakano, H., Fukase, K., Nu´n˜ez, G.,
and Inohara, N. (2008). A critical role of RICK/RIP2 polyubiquitination in Nod-
induced NF-kappaB activation. EMBO J. 27, 373–383.
Hasegawa, M., Yamazaki, T., Kamada, N., Tawaratsumida, K., Kim, Y.G.,
Nu´n˜ez, G., and Inohara, N. (2011). Nucleotide-binding oligomerization domain
1 mediates recognition of Clostridium difficile and induces neutrophil recruit-
ment and protection against the pathogen. J. Immunol. 186, 4872–4880.
Hedl, M., Li, J., Cho, J.H., and Abraham, C. (2007). Chronic stimulation of Nod2
mediates tolerance to bacterial products. Proc. Natl. Acad. Sci. USA 104,
19440–19445.
Hisamatsu, T., Suzuki, M., Reinecker, H.C., Nadeau, W.J., McCormick, B.A.,
and Podolsky, D.K. (2003). CARD15/NOD2 functions as an antibacterial factor
in human intestinal epithelial cells. Gastroenterology 124, 993–1000.
Hitotsumatsu, O., Ahmad, R.C., Tavares, R., Wang, M., Philpott, D., Turer,
E.E., Lee, B.L., Shiffin, N., Advincula, R., Malynn, B.A., et al. (2008). The ubiq-
uitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain
containing 2-triggered signals. Immunity 28, 381–390.
Homer, C.R., Richmond, A.L., Rebert, N.A., Achkar, J.P., and McDonald, C.
(2010). ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial
pathway implicated in Crohn’s disease pathogenesis. Gastroenterology 139,
1630–1641, e1–e2.
Hruz, P., Zinkernagel, A.S., Jenikova, G., Botwin, G.J., Hugot, J.P., Karin, M.,
Nizet, V., and Eckmann, L. (2009). NOD2 contributes to cutaneous defense
against Staphylococcus aureus through alpha-toxin-dependent innate im-
mune activation. Proc. Natl. Acad. Sci. USA 106, 12873–12878.
Hu, Z., Yan, C., Liu, P., Huang, Z., Ma, R., Zhang, C., Wang, R., Zhang, Y., Mar-
tinon, F., Miao, D., et al. (2013). Crystal structure of NLRC4 reveals its autoin-
hibition mechanism. Science 341, 172–175.
Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Ce´zard, J.P., Belaiche, J.,
Almer, S., Tysk, C., O’Morain, C.A., Gassull, M., et al. (2001). Association of
NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease.
Nature 411, 599–603.
Hugot, J.P., Zaccaria, I., Cavanaugh, J., Yang, H., Vermeire, S., Lappalainen,
M., Schreiber, S., Annese, V., Jewell, D.P., Fowler, E.V., et al.; IBD International
Genetics Consortium (2007). Prevalence of CARD15/NOD2 mutations in
Caucasian healthy people. Am. J. Gastroenterol. 102, 1259–1267.
Inohara, N., Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S., Carrio, R.,
Merino, J., Liu, D., Ni, J., and Nu´n˜ez, G. (1999). Nod1, an Apaf-1-like activator
of caspase-9 and nuclear factor-kappaB. J. Biol. Chem. 274, 14560–14567.
Inohara, N., Ogura, Y., Chen, F.F., Muto, A., and Nun˜ez, G. (2001). Human
Nod1 confers responsiveness to bacterial lipopolysaccharides. J. Biol.
Chem. 276, 2551–2554.906 Immunity 41, December 18, 2014 ª2014 Elsevier Inc.Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., Fukase,
K., Inamura, S., Kusumoto, S., Hashimoto, M., et al. (2003). Host recognition of
bacterial muramyl dipeptidemediated through NOD2. Implications for Crohn’s
disease. J. Biol. Chem. 278, 5509–5512.
Irving, A.T., Mimuro, H., Kufer, T.A., Lo, C., Wheeler, R., Turner, L.J., Thomas,
B.J., Malosse, C., Gantier, M.P., Casillas, L.N., et al. (2014). The immune re-
ceptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early
endosomes to promote autophagy and inflammatory signaling. Cell Host
Microbe 15, 623–635.
Jakopin, Z. (2014). Nucleotide-binding oligomerization domain (NOD) inhibi-
tors: a rational approach toward inhibition of NOD signaling pathway.
J. Med. Chem. 57, 6897–6918.
Jakopin, Z., Gobec, M., Mlinaric-Rascan, I., and Sollner Dolenc, M. (2012).
Immunomodulatory properties of novel nucleotide oligomerization domain 2
(nod2) agonistic desmuramyldipeptides. J. Med. Chem. 55, 6478–6488.
Jakopin, Z., Gobec,M., Kodela, J., Hazdovac, T., Mlinaric-Rascan, I., and Soll-
ner Dolenc, M. (2013). Synthesis of conformationally constrained g-D-glu-
tamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding
oligomerization domain protein 1 (Nod1). Eur. J. Med. Chem. 69, 232–243.
Jiao, Y., Darzi, Y., Tawaratsumida, K., Marchesan, J.T., Hasegawa, M., Moon,
H., Chen, G.Y., Nu´n˜ez, G., Giannobile, W.V., Raes, J., and Inohara, N. (2013).
Induction of bone loss by pathobiont-mediated Nod1 signaling in the oral cav-
ity. Cell Host Microbe 13, 595–601.
Jiao, Y., Hasegawa, M., and Inohara, N. (2014). Emerging roles of immunosti-
mulatory oral bacteria in periodontitis development. Trends Microbiol. 22,
157–163.
Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y.,
Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., et al.; International IBD
Genetics Consortium (IIBDGC) (2012). Host-microbe interactions have shaped
the genetic architecture of inflammatory bowel disease. Nature 491, 119–124.
Jun, J.C., Cominelli, F., and Abbott, D.W. (2013). RIP2 activity in inflammatory
disease and implications for novel therapeutics. J. Leukoc. Biol. 94, 927–932.
Khan, P.M., Correa, R.G., Divlianska, D.B., Peddibhotla, S., Sessions, E.H.,
Magnuson, G., Brown, B., Suyama, E., Yuan, H., Mangravita-Novo, A., et al.
(2011). Identification of Inhibitors of NOD1-Induced Nuclear Factor-kB Activa-
tion. ACS Med. Chem. Lett. 2, 780–785.
Kim, J.G., Lee, S.J., and Kagnoff, M.F. (2004). Nod1 is an essential signal
transducer in intestinal epithelial cells infected with bacteria that avoid recog-
nition by toll-like receptors. Infect. Immun. 72, 1487–1495.
Kim, Y.G., Park, J.H., Daignault, S., Fukase, K., and Nu´n˜ez, G. (2008a). Cross-
tolerization between Nod1 and Nod2 signaling results in reduced refractori-
ness to bacterial infection in Nod2-deficient macrophages. J. Immunol. 181,
4340–4346.
Kim, Y.G., Park, J.H., Shaw, M.H., Franchi, L., Inohara, N., and Nu´n˜ez, G.
(2008b). The cytosolic sensors Nod1 and Nod2 are critical for bacterial recog-
nition and host defense after exposure to Toll-like receptor ligands. Immunity
28, 246–257.
Kim, M.L., Jeong, H.G., Kasper, C.A., and Arrieumerlou, C. (2010). IKKa con-
tributes to canonical NF-kB activation downstream of Nod1-mediated pepti-
doglycan recognition. PLoS ONE 5, e15371.
Kim, Y.G., Kamada, N., Shaw, M.H., Warner, N., Chen, G.Y., Franchi, L., and
Nu´n˜ez, G. (2011a). The Nod2 sensor promotes intestinal pathogen eradication
via the chemokine CCL2-dependent recruitment of inflammatory monocytes.
Immunity 34, 769–780.
Kim, Y.G., Shaw, M.H., Warner, N., Park, J.H., Chen, F., Ogura, Y., and Nu´n˜ez,
G. (2011b). Cutting edge: Crohn’s disease-associated Nod2 mutation limits
production of proinflammatory cytokines to protect the host from Entero-
coccus faecalis-induced lethality. J. Immunol. 187, 2849–2852.
Kim, Y.G., Udayanga, K.G., Totsuka, N., Weinberg, J.B., Nu´n˜ez, G., and Shi-
buya, A. (2014). Gut dysbiosis promotes M2 macrophage polarization and
allergic airway inflammation via fungi-induced PGE2. Cell Host Microbe 15,
95–102.
Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed, S.,
Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H.G., et al. (2012).
Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection
Immunity
Reviewfrom reinfection via epigenetic reprogramming of monocytes. Proc. Natl.
Acad. Sci. USA 109, 17537–17542.
Kobayashi, K.S., Chamaillard, M., Ogura, Y., Henegariu, O., Inohara, N.,
Nun˜ez, G., and Flavell, R.A. (2005). Nod2-dependent regulation of innate
and adaptive immunity in the intestinal tract. Science 307, 731–734.
Kramer, M., Netea, M.G., de Jong, D.J., Kullberg, B.J., and Adema, G.J.
(2006). Impaired dendritic cell function in Crohn’s disease patients with
NOD2 3020insC mutation. J. Leukoc. Biol. 79, 860–866.
Kufer, T.A., Kremmer, E., Banks, D.J., and Philpott, D.J. (2006). Role for erbin in
bacterial activation of Nod2. Infect. Immun. 74, 3115–3124.
Lala, S., Ogura, Y., Osborne, C., Hor, S.Y., Bromfield, A., Davies, S., Ogunbiyi,
O., Nun˜ez, G., and Keshav, S. (2003). Crohn’s disease and the NOD2 gene: a
role for paneth cells. Gastroenterology 125, 47–57.
Laroui, H., Yan, Y., Narui, Y., Ingersoll, S.A., Ayyadurai, S., Charania, M.A.,
Zhou, F., Wang, B., Salaita, K., Sitaraman, S.V., and Merlin, D. (2011). L-Ala-
g-D-Glu-meso-diaminopimelic acid (DAP) interacts directly with leucine-rich
region domain of nucleotide-binding oligomerization domain 1, increasing
phosphorylation activity of receptor-interacting serine/threonine-protein ki-
nase 2 and its interaction with nucleotide-binding oligomerization domain 1.
J. Biol. Chem. 286, 31003–31013.
Lechtenberg, B.C., Mace, P.D., and Riedl, S.J. (2014). Structural mechanisms
in NLR inflammasome signaling. Curr. Opin. Struct. Biol. 29C, 17–25.
Lee, J., Tattoli, I., Wojtal, K.A., Vavricka, S.R., Philpott, D.J., and Girardin, S.E.
(2009). pH-dependent internalization of muramyl peptides from early endo-
somes enables Nod1 and Nod2 signaling. J. Biol. Chem. 284, 23818–23829.
Lee, K.H., Biswas, A., Liu, Y.J., and Kobayashi, K.S. (2012). Proteasomal
degradation of Nod2 protein mediates tolerance to bacterial cell wall compo-
nents. J. Biol. Chem. 287, 39800–39811.
Lipinski, S., Grabe, N., Jacobs, G., Billmann-Born, S., Till, A., Ha¨sler, R., Aden,
K., Paulsen, M., Arlt, A., Kraemer, L., et al. (2012). RNAi screening identifies
mediators of NOD2 signaling: implications for spatial specificity of MDP recog-
nition. Proc. Natl. Acad. Sci. USA 109, 21426–21431.
Maeda, S., Hsu, L.C., Liu, H., Bankston, L.A., Iimura, M., Kagnoff, M.F., Eck-
mann, L., and Karin, M. (2005). Nod2 mutation in Crohn’s disease potentiates
NF-kappaB activity and IL-1beta processing. Science 307, 734–738.
Magalhaes, J.G., Fritz, J.H., Le Bourhis, L., Sellge, G., Travassos, L.H., Selva-
nantham, T., Girardin, S.E., Gommerman, J.L., and Philpott, D.J. (2008). Nod2-
dependent Th2 polarization of antigen-specific immunity. J. Immunol. 181,
7925–7935.
Magalhaes, J.G., Rubino, S.J., Travassos, L.H., Le Bourhis, L., Duan, W.,
Sellge, G., Geddes, K., Reardon, C., Lechmann, M., Carneiro, L.A., et al.
(2011). Nucleotide oligomerization domain-containing proteins instruct T cell
helper type 2 immunity through stromal activation. Proc. Natl. Acad. Sci.
USA 108, 14896–14901.
Maisonneuve, C., Bertholet, S., Philpott, D.J., and De Gregorio, E. (2014).
Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
Proc. Natl. Acad. Sci. USA 111, 12294–12299.
Marinis, J.M., Homer, C.R., McDonald, C., and Abbott, D.W. (2011). A novel
motif in the Crohn’s disease susceptibility protein, NOD2, allows TRAF4 to
down-regulate innate immune responses. J. Biol. Chem. 286, 1938–1950.
Masumoto, J., Yang, K., Varambally, S., Hasegawa, M., Tomlins, S.A., Qiu, S.,
Fujimoto, Y., Kawasaki, A., Foster, S.J., Horie, Y., et al. (2006). Nod1 acts as an
intracellular receptor to stimulate chemokine production and neutrophil
recruitment in vivo. J. Exp. Med. 203, 203–213.
Mo, J., Boyle, J.P., Howard, C.B., Monie, T.P., Davis, B.K., and Duncan, J.A.
(2012). Pathogen sensing by nucleotide-binding oligomerization domain-con-
taining protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide
and ATP. J. Biol. Chem. 287, 23057–23067.
Nakamura, N., Lill, J.R., Phung, Q., Jiang, Z., Bakalarski, C., de Mazie`re, A.,
Klumperman, J., Schlatter, M., Delamarre, L., and Mellman, I. (2014). Endo-
somes are specialized platforms for bacterial sensing and NOD2 signalling.
Nature 509, 240–244.
Nigro, G., Rossi, R., Commere, P.H., Jay, P., and Sansonetti, P.J. (2014). The
cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protectionand links microbes to gut epithelial regeneration. Cell Host Microbe 15,
792–798.
Noguchi, E., Homma, Y., Kang, X., Netea, M.G., and Ma, X. (2009). A Crohn’s
disease-associated NOD2 mutation suppresses transcription of human IL10
by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat. Immu-
nol. 10, 471–479.
Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F., Ramos, R., Brit-
ton, H., Moran, T., Karaliuskas, R., Duerr, R.H., et al. (2001a). A frameshift mu-
tation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411,
603–606.
Ogura, Y., Inohara, N., Benito, A., Chen, F.F., Yamaoka, S., and Nunez, G.
(2001b). Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes
and activates NF-kappaB. J. Biol. Chem. 276, 4812–4818.
Ogura, Y., Lala, S., Xin, W., Smith, E., Dowds, T.A., Chen, F.F., Zimmermann,
E., Tretiakova, M., Cho, J.H., Hart, J., et al. (2003). Expression of NOD2 in
Paneth cells: a possible link to Crohn’s ileitis. Gut 52, 1591–1597.
Opitz, B., Pu¨schel, A., Schmeck, B., Hocke, A.C., Rosseau, S., Hammersch-
midt, S., Schumann, R.R., Suttorp, N., and Hippenstiel, S. (2004). Nucleo-
tide-binding oligomerization domain proteins are innate immune receptors
for internalized Streptococcus pneumoniae. J. Biol. Chem. 279, 36426–36432.
Park, J.H., Kim, Y.G., Shaw, M., Kanneganti, T.D., Fujimoto, Y., Fukase, K., In-
ohara, N., and Nu´n˜ez, G. (2007). Nod1/RICK and TLR signaling regulate che-
mokine and antimicrobial innate immune responses in mesothelial cells.
J. Immunol. 179, 514–521.
Park, B.S., Song, D.H., Kim, H.M., Choi, B.S., Lee, H., and Lee, J.O. (2009). The
structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.
Nature 458, 1191–1195.
Pauleau, A.L., and Murray, P.J. (2003). Role of nod2 in the response of macro-
phages to toll-like receptor agonists. Mol. Cell. Biol. 23, 7531–7539.
Petnicki-Ocwieja, T., Hrncir, T., Liu, Y.J., Biswas, A., Hudcovic, T., Tlaskalova-
Hogenova, H., and Kobayashi, K.S. (2009). Nod2 is required for the regulation
of commensal microbiota in the intestine. Proc. Natl. Acad. Sci. USA 106,
15813–15818.
Philpott, D.J., Sorbara, M.T., Robertson, S.J., Croitoru, K., and Girardin, S.E.
(2014). NOD proteins: regulators of inflammation in health and disease. Nat.
Rev. Immunol. 14, 9–23.
Ramanan, D., Tang, M.S., Bowcutt, R., Loke, P., and Cadwell, K. (2014). Bac-
terial sensor Nod2 prevents inflammation of the small intestine by restricting
the expansion of the commensal Bacteroides vulgatus. Immunity 41, 311–324.
Rehman, A., Sina, C., Gavrilova, O., Ha¨sler, R., Ott, S., Baines, J.F., Schreiber,
S., and Rosenstiel, P. (2011). Nod2 is essential for temporal development of in-
testinal microbial communities. Gut 60, 1354–1362.
Rickard, D.J., Sehon, C.A., Kasparcova, V., Kallal, L.A., Zeng, X., Montoute,
M.N., Chordia, T., Poore, D.D., Li, H., Wu, Z., et al. (2013). Identification of
benzimidazole diamides as selective inhibitors of the nucleotide-binding olig-
omerization domain 2 (NOD2) signaling pathway. PLoS ONE 8, e69619.
Riedl, S.J., Li,W., Chao, Y., Schwarzenbacher, R., and Shi, Y. (2005). Structure
of the apoptotic protease-activating factor 1 bound to ADP. Nature 434,
926–933.
Robertson, S.J., Zhou, J.Y., Geddes, K., Rubino, S.J., Cho, J.H., Girardin, S.E.,
and Philpott, D.J. (2013). Nod1 and Nod2 signaling does not alter the compo-
sition of intestinal bacterial communities at homeostasis. Gut Microbes 4,
222–231.
Rubino, S.J., Magalhaes, J.G., Philpott, D., Bahr, G.M., Blanot, D., and Girar-
din, S.E. (2013). Identification of a synthetic muramyl peptide derivative with
enhanced Nod2 stimulatory capacity. Innate Immun 19, 493–503.
Salucci, V., Rimoldi, M., Penati, C., Sampietro, G.M., van Duist, M.M.,Matteoli,
G., Saibeni, S., Vecchi, M., Ardizzone, S., Porro, G.B., and Rescigno, M.
(2008). Monocyte-derived dendritic cells from Crohn patients show differential
NOD2/CARD15-dependent immune responses to bacteria. Inflamm. Bowel
Dis. 14, 812–818.
Sasawatari, S., Okamura, T., Kasumi, E., Tanaka-Furuyama, K., Yanobu-Taka-
nashi, R., Shirasawa, S., Kato, N., and Toyama-Sorimachi, N. (2011). The
solute carrier family 15A4 regulates TLR9 and NOD1 functions in the innate im-
mune system and promotes colitis in mice. Gastroenterology 140, 1513–1525.Immunity 41, December 18, 2014 ª2014 Elsevier Inc. 907
Immunity
ReviewShanahan, M.T., Carroll, I.M., Grossniklaus, E., White, A., von Furstenberg,
R.J., Barner, R., Fodor, A.A., Henning, S.J., Sartor, R.B., and Gulati, A.S.
(2014). Mouse Paneth cell antimicrobial function is independent of Nod2.
Gut 63, 903–910.
Simms, L.A., Doecke, J.D.,Walsh, M.D., Huang, N., Fowler, E.V., and Radford-
Smith, G.L. (2008). Reduced alpha-defensin expression is associated with
inflammation and not NOD2 mutation status in ileal Crohn’s disease. Gut 57,
903–910.
Tada, H., Aiba, S., Shibata, K., Ohteki, T., and Takada, H. (2005). Synergistic
effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human
dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect.
Immun. 73, 7967–7976.
Tanabe, T., Chamaillard, M., Ogura, Y., Zhu, L., Qiu, S., Masumoto, J., Ghosh,
P., Moran, A., Predergast, M.M., Tromp, G., et al. (2004). Regulatory regions
and critical residues of NOD2 involved in muramyl dipeptide recognition.
EMBO J. 23, 1587–1597.
Tao, M., Scacheri, P.C., Marinis, J.M., Harhaj, E.W., Matesic, L.E., and Abbott,
D.W. (2009). ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influ-
ence inflammatory signaling pathways. Curr. Biol. 19, 1255–1263.
Thay, B., Damm, A., Kufer, T.A., Wai, S.N., and Oscarsson, J. (2014). Aggrega-
tibacter actinomycetemcomitans outer membrane vesicles are internalized in
human host cells and trigger NOD1- and NOD2-dependent NF-kB activation.
Infect. Immun. 82, 4034–4046.
Theivanthiran, B., Batra, S., Balamayooran, G., Cai, S., Kobayashi, K., Flavell,
R.A., and Jeyaseelan, S. (2012). NOD2 signaling contributes to host defense in
the lungs against Escherichia coli infection. Infect. Immun. 80, 2558–2569.
Tigno-Aranjuez, J.T., Asara, J.M., and Abbott, D.W. (2010). Inhibition of RIP2’s
tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev.
24, 2666–2677.
Tigno-Aranjuez, J.T., Benderitter, P., Rombouts, F., Deroose, F., Bai, X., Mat-
tioli, B., Cominelli, F., Pizarro, T.T., Hoflack, J., and Abbott, D.W. (2014). In vivo
inhibition of RIPK2 kinase alleviates inflammatory disease. J. Biol. Chem. 289,
29651–29664, http://dx.doi.org/10.1074/2014.09.11.
Travassos, L.H., Carneiro, L.A., Girardin, S.E., Boneca, I.G., Lemos, R., Bozza,
M.T., Domingues, R.C., Coyle, A.J., Bertin, J., Philpott, D.J., and Plotkowski,
M.C. (2005). Nod1 participates in the innate immune response to Pseudo-
monas aeruginosa. J. Biol. Chem. 280, 36714–36718.
Travassos, L.H., Carneiro, L.A., Ramjeet, M., Hussey, S., Kim, Y.G., Magal-
ha˜es, J.G., Yuan, L., Soares, F., Chea, E., Le Bourhis, L., et al. (2010). Nod1
and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane
at the site of bacterial entry. Nat. Immunol. 11, 55–62.
van Beelen, A.J., Zelinkova, Z., Taanman-Kueter, E.W., Muller, F.J., Hommes,
D.W., Zaat, S.A., Kapsenberg, M.L., and de Jong, E.C. (2007). Stimulation of
the intracellular bacterial sensor NOD2 programs dendritic cells to promote
interleukin-17 production in human memory T cells. Immunity 27, 660–669.
van Heel, D.A., Ghosh, S., Butler, M., Hunt, K.A., Lundberg, A.M., Ahmad, T.,
McGovern, D.P., Onnie, C., Negoro, K., Goldthorpe, S., et al. (2005). Muramyl
dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s dis-
ease. Lancet 365, 1794–1796.
Ver Heul, A.M., Fowler, C.A., Ramaswamy, S., and Piper, R.C. (2013). Ubiquitin
regulates caspase recruitment domain-mediated signaling by nucleotide-908 Immunity 41, December 18, 2014 ª2014 Elsevier Inc.binding oligomerization domain-containing proteins NOD1 and NOD2.
J. Biol. Chem. 288, 6890–6902.
Ver Heul, A.M., Gakhar, L., Piper, R.C., and Subramanian, R. (2014). Crystal
structure of a complex of NOD1 CARD and ubiquitin. PLoS ONE 9, e104017.
Viala, J., Chaput, C., Boneca, I.G., Cardona, A., Girardin, S.E., Moran, A.P.,
Athman, R., Me´met, S., Huerre, M.R., Coyle, A.J., et al. (2004). Nod1 responds
to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island.
Nat. Immunol. 5, 1166–1174.
Wagener, J., Malireddi, R.K., Lenardon, M.D., Ko¨berle, M., Vautier, S., Mac-
Callum, D.M., Biedermann, T., Schaller, M., Netea, M.G., Kanneganti, T.D.,
et al. (2014). Fungal chitin dampens inflammation through IL-10 induction
mediated by NOD2 and TLR9 activation. PLoS Pathog. 10, e1004050.
Warner, N., Burberry, A., Pliakas, M., McDonald, C., and Nu´n˜ez, G. (2014). A
genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-kB
(NF-kB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secre-
tion. J. Biol. Chem. 289, 28213–28224.
Watanabe, T., Kitani, A., Murray, P.J.,Wakatsuki, Y., Fuss, I.J., and Strober,W.
(2006). Nucleotide binding oligomerization domain 2 deficiency leads to dysre-
gulated TLR2 signaling and induction of antigen-specific colitis. Immunity 25,
473–485.
Watanabe, T., Asano, N., Fichtner-Feigl, S., Gorelick, P.L., Tsuji, Y., Matsu-
moto, Y., Chiba, T., Fuss, I.J., Kitani, A., and Strober, W. (2010). NOD1 contrib-
utes to mouse host defense against Helicobacter pylori via induction of type I
IFN and activation of the ISGF3 signaling pathway. J. Clin. Invest. 120, 1645–
1662.
Wehkamp, J., Harder, J., Weichenthal, M., Schwab, M., Scha¨ffeler, E., Schlee,
M., Herrlinger, K.R., Stallmach, A., Noack, F., Fritz, P., et al. (2004). NOD2
(CARD15) mutations in Crohn’s disease are associated with diminished
mucosal alpha-defensin expression. Gut 53, 1658–1664.
Wehkamp, J., Salzman, N.H., Porter, E., Nuding, S., Weichenthal, M., Petras,
R.E., Shen, B., Schaeffeler, E., Schwab, M., Linzmeier, R., et al. (2005).
Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc. Natl.
Acad. Sci. USA 102, 18129–18134.
Yang, S., Wang, B., Humphries, F., Jackson, R., Healy, M.E., Bergin, R.,
Aviello, G., Hall, B., McNamara, D., Darby, T., et al. (2013). Pellino3 ubiquiti-
nates RIP2 and mediates Nod2-induced signaling and protective effects in
colitis. Nat. Immunol. 14, 927–936.
Zeissig, Y., Petersen, B.S., Milutinovic, S., Bosse, E., Mayr, G., Peuker, K.,
Hartwig, J., Keller, A., Kohl, M., Laass, M.W., et al. (2014). XIAP variants in
male Crohn’s disease. Gut.. http://dx.doi.org/10.1136/2014.02.26.
Zhang, R., Zhao, J., Song, Y., Wang, X., Wang, L., Xu, J., Song, C., and Liu, F.
(2014). The E3 ligase RNF34 is a novel negative regulator of the NOD1
pathway. Cell. Physiol. Biochem. 33, 1954–1962.
Zilbauer, M., Dorrell, N., Elmi, A., Lindley, K.J., Schu¨ller, S., Jones, H.E., Klein,
N.J., Nu´nez, G., Wren, B.W., and Bajaj-Elliott, M. (2007). A major role for intes-
tinal epithelial nucleotide oligomerization domain 1 (NOD1) in eliciting host
bactericidal immune responses to Campylobacter jejuni. Cell. Microbiol. 9,
2404–2416.
Zurek, B., Schoultz, I., Neerincx, A., Napolitano, L.M., Birkner, K., Bennek, E.,
Sellge, G., Lerm, M., Meroni, G., So¨derholm, J.D., and Kufer, T.A. (2012).
TRIM27 negatively regulates NOD2 by ubiquitination and proteasomal degra-
dation. PLoS ONE 7, e41255.
